UBS analyst Daniel Brennan raised his price target on Exact Sciences (EXAS) to $109 from $100 following meetings with management. The analyst raised his doctor additions forecast as well as his Street-high revenue forecasts and still sees room for upside. He sees the additions upside coming as the result of a doubling of ad spending, the addition of Pfizer (PFE and its salesforce, and the doubling of its own salesforce. Brennan reiterated his Buy rating on Exact Sciences shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.